Mylan has increased the cost of purchasing a life saving device, the Epipen, 500% since 2007 from 100 to 600. The device dispenses about 1.00 worth of medicine. The product has a shelf life of only 1 year. In the same amount of time, the CEO of Mylan increased her salary 670% to 18.9 Million per year. The company has a monopoly on the product, and must be stopped from forcing parents to choose between having a roof over their heads or providing life saving medicine for their children.
This is historical material “frozen in time”. The website is no longer updated and links to external websites and some internal pages may not work.
